Clinical Study

A Randomized, Multicenter, Double-Blind Phase 2 Study Of Palbociclib Plus Cetuximab Versus Cetuximab For The Treatment Of Human Papillomavirus-Negative, Cetuximab-Naive Patients With Recurrent/Metastatic Squamous Cell Carcinoma Of The Head And Neck After

Posted Date: Oct 11, 2017

  • Investigator: Trisha Wise-Draper
  • Specialties: Hematology/Oncology, Oncology, Cancer
  • Type of Study: Drug

The purpose of this study is to compare the effects of the study drug, palbociclib in combination with cetuximab against placebo in combination with cetuximab. Palbociclib is not approved to treat head and neck cancer, meaning it is an investigational drug for the purpose of this study.


To Be Eligible To Participate In This Study, Participants Must Have Head And Neck Cancer That Cannot Be Treated By Surgery Or Radiation Therapy.


Pfizer A5481044, Cancer, Phase Ii, Head & Neck

For More Information:

Uc Cancer Institute

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.